nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A7—Ifosfamide—testicular cancer	0.123	0.177	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.123	0.177	CbGbCtD
Ondansetron—CYP3A5—Ifosfamide—testicular cancer	0.092	0.132	CbGbCtD
Ondansetron—CYP2C9—Ifosfamide—testicular cancer	0.0617	0.0889	CbGbCtD
Ondansetron—CYP2E1—Etoposide—testicular cancer	0.0566	0.0815	CbGbCtD
Ondansetron—CYP3A5—Etoposide—testicular cancer	0.0439	0.0633	CbGbCtD
Ondansetron—CYP3A4—Ifosfamide—testicular cancer	0.0359	0.0517	CbGbCtD
Ondansetron—CYP1A2—Etoposide—testicular cancer	0.0327	0.0471	CbGbCtD
Ondansetron—CYP2C9—Cisplatin—testicular cancer	0.03	0.0432	CbGbCtD
Ondansetron—CYP2D6—Vinblastine—testicular cancer	0.0299	0.0431	CbGbCtD
Ondansetron—CYP3A4—Vinblastine—testicular cancer	0.019	0.0274	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—testicular cancer	0.0184	0.0265	CbGbCtD
Ondansetron—CYP3A4—Etoposide—testicular cancer	0.0171	0.0247	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—testicular cancer	0.0117	0.0168	CbGbCtD
Ondansetron—SLC47A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000821	0.177	CbGpPWpGaD
Ondansetron—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000529	0.114	CbGpPWpGaD
Ondansetron—Cough—Etoposide—testicular cancer	0.000481	0.0016	CcSEcCtD
Ondansetron—Tachycardia—Cisplatin—testicular cancer	0.00048	0.00159	CcSEcCtD
Ondansetron—Asthenia—Bleomycin—testicular cancer	0.000478	0.00159	CcSEcCtD
Ondansetron—Convulsion—Etoposide—testicular cancer	0.000478	0.00159	CcSEcCtD
Ondansetron—Skin disorder—Cisplatin—testicular cancer	0.000477	0.00158	CcSEcCtD
Ondansetron—Asthma—Methotrexate—testicular cancer	0.000474	0.00157	CcSEcCtD
Ondansetron—Liver function test abnormal—Epirubicin—testicular cancer	0.000474	0.00157	CcSEcCtD
Ondansetron—Pruritus—Bleomycin—testicular cancer	0.000472	0.00157	CcSEcCtD
Ondansetron—Feeling abnormal—Ifosfamide—testicular cancer	0.00047	0.00156	CcSEcCtD
Ondansetron—Chest pain—Etoposide—testicular cancer	0.00047	0.00156	CcSEcCtD
Ondansetron—Hypokalaemia—Epirubicin—testicular cancer	0.000467	0.00155	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000466	0.00155	CcSEcCtD
Ondansetron—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000466	0.00155	CcSEcCtD
Ondansetron—Discomfort—Etoposide—testicular cancer	0.000464	0.00154	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000462	0.00153	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000462	0.00153	CcSEcCtD
Ondansetron—Hypotension—Cisplatin—testicular cancer	0.000459	0.00152	CcSEcCtD
Ondansetron—Hypersensitivity—Dactinomycin—testicular cancer	0.000458	0.00152	CcSEcCtD
Ondansetron—Urticaria—Ifosfamide—testicular cancer	0.000453	0.0015	CcSEcCtD
Ondansetron—Abdominal pain—Ifosfamide—testicular cancer	0.000451	0.0015	CcSEcCtD
Ondansetron—Body temperature increased—Ifosfamide—testicular cancer	0.000451	0.0015	CcSEcCtD
Ondansetron—Anaphylactic shock—Etoposide—testicular cancer	0.00045	0.00149	CcSEcCtD
Ondansetron—Asthenia—Dactinomycin—testicular cancer	0.000446	0.00148	CcSEcCtD
Ondansetron—Asthma—Epirubicin—testicular cancer	0.000444	0.00147	CcSEcCtD
Ondansetron—Dysuria—Methotrexate—testicular cancer	0.000443	0.00147	CcSEcCtD
Ondansetron—Paraesthesia—Cisplatin—testicular cancer	0.000441	0.00146	CcSEcCtD
Ondansetron—Tachycardia—Etoposide—testicular cancer	0.000439	0.00146	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—testicular cancer	0.000439	0.00146	CcSEcCtD
Ondansetron—Dyspnoea—Cisplatin—testicular cancer	0.000438	0.00145	CcSEcCtD
Ondansetron—Skin disorder—Etoposide—testicular cancer	0.000437	0.00145	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—testicular cancer	0.000432	0.00143	CcSEcCtD
Ondansetron—Angina pectoris—Epirubicin—testicular cancer	0.000432	0.00143	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000428	0.00142	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000428	0.00142	CcSEcCtD
Ondansetron—Diarrhoea—Dactinomycin—testicular cancer	0.000426	0.00141	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000424	0.00141	CcSEcCtD
Ondansetron—Vomiting—Bleomycin—testicular cancer	0.000424	0.00141	CcSEcCtD
Ondansetron—Drowsiness—Methotrexate—testicular cancer	0.000423	0.0014	CcSEcCtD
Ondansetron—Hypotension—Etoposide—testicular cancer	0.000421	0.0014	CcSEcCtD
Ondansetron—Rash—Bleomycin—testicular cancer	0.00042	0.0014	CcSEcCtD
Ondansetron—Pain—Cisplatin—testicular cancer	0.00042	0.00139	CcSEcCtD
Ondansetron—Dermatitis—Bleomycin—testicular cancer	0.00042	0.00139	CcSEcCtD
Ondansetron—Hypersensitivity—Ifosfamide—testicular cancer	0.00042	0.00139	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000419	0.00139	CcSEcCtD
Ondansetron—Dysuria—Epirubicin—testicular cancer	0.000415	0.00138	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—testicular cancer	0.000411	0.00136	CcSEcCtD
Ondansetron—Asthenia—Ifosfamide—testicular cancer	0.000409	0.00136	CcSEcCtD
Ondansetron—Feeling abnormal—Cisplatin—testicular cancer	0.000405	0.00134	CcSEcCtD
Ondansetron—Paraesthesia—Etoposide—testicular cancer	0.000404	0.00134	CcSEcCtD
Ondansetron—Pruritus—Ifosfamide—testicular cancer	0.000403	0.00134	CcSEcCtD
Ondansetron—Dyspnoea—Etoposide—testicular cancer	0.000401	0.00133	CcSEcCtD
Ondansetron—Somnolence—Etoposide—testicular cancer	0.0004	0.00133	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—testicular cancer	0.0004	0.00133	CcSEcCtD
Ondansetron—Hepatobiliary disease—Methotrexate—testicular cancer	0.0004	0.00133	CcSEcCtD
Ondansetron—Drowsiness—Epirubicin—testicular cancer	0.000396	0.00131	CcSEcCtD
Ondansetron—Vomiting—Dactinomycin—testicular cancer	0.000395	0.00131	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000392	0.0013	CcSEcCtD
Ondansetron—Rash—Dactinomycin—testicular cancer	0.000392	0.0013	CcSEcCtD
Ondansetron—Diarrhoea—Ifosfamide—testicular cancer	0.00039	0.00129	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Etoposide—testicular cancer	0.000389	0.00129	CcSEcCtD
Ondansetron—Body temperature increased—Cisplatin—testicular cancer	0.000388	0.00129	CcSEcCtD
Ondansetron—Fatigue—Etoposide—testicular cancer	0.000388	0.00129	CcSEcCtD
Ondansetron—Constipation—Etoposide—testicular cancer	0.000385	0.00128	CcSEcCtD
Ondansetron—Pain—Etoposide—testicular cancer	0.000385	0.00128	CcSEcCtD
Ondansetron—Urinary tract infection—Epirubicin—testicular cancer	0.000385	0.00128	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—testicular cancer	0.000384	0.00127	CcSEcCtD
Ondansetron—Haemoglobin—Methotrexate—testicular cancer	0.000381	0.00127	CcSEcCtD
Ondansetron—Haemorrhage—Methotrexate—testicular cancer	0.000379	0.00126	CcSEcCtD
Ondansetron—Dizziness—Ifosfamide—testicular cancer	0.000377	0.00125	CcSEcCtD
Ondansetron—Hepatobiliary disease—Epirubicin—testicular cancer	0.000374	0.00124	CcSEcCtD
Ondansetron—SLC47A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000373	0.0803	CbGpPWpGaD
Ondansetron—HTR4—G alpha (s) signalling events—INSL3—testicular cancer	0.000373	0.0803	CbGpPWpGaD
Ondansetron—Feeling abnormal—Etoposide—testicular cancer	0.000371	0.00123	CcSEcCtD
Ondansetron—Gastrointestinal pain—Etoposide—testicular cancer	0.000368	0.00122	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—testicular cancer	0.000366	0.00121	CcSEcCtD
Ondansetron—Visual impairment—Methotrexate—testicular cancer	0.000366	0.00121	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000363	0.0012	CcSEcCtD
Ondansetron—Vomiting—Ifosfamide—testicular cancer	0.000362	0.0012	CcSEcCtD
Ondansetron—Hypersensitivity—Cisplatin—testicular cancer	0.000362	0.0012	CcSEcCtD
Ondansetron—Bradycardia—Epirubicin—testicular cancer	0.000362	0.0012	CcSEcCtD
Ondansetron—Rash—Ifosfamide—testicular cancer	0.000359	0.00119	CcSEcCtD
Ondansetron—Dermatitis—Ifosfamide—testicular cancer	0.000359	0.00119	CcSEcCtD
Ondansetron—Erythema multiforme—Methotrexate—testicular cancer	0.000359	0.00119	CcSEcCtD
Ondansetron—Urticaria—Etoposide—testicular cancer	0.000358	0.00119	CcSEcCtD
Ondansetron—Haemoglobin—Epirubicin—testicular cancer	0.000357	0.00118	CcSEcCtD
Ondansetron—Abdominal pain—Etoposide—testicular cancer	0.000356	0.00118	CcSEcCtD
Ondansetron—Body temperature increased—Etoposide—testicular cancer	0.000356	0.00118	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—testicular cancer	0.000356	0.00118	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—testicular cancer	0.000355	0.00118	CcSEcCtD
Ondansetron—Eye disorder—Methotrexate—testicular cancer	0.000355	0.00118	CcSEcCtD
Ondansetron—Asthenia—Cisplatin—testicular cancer	0.000353	0.00117	CcSEcCtD
Ondansetron—Cardiac disorder—Methotrexate—testicular cancer	0.000352	0.00117	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000346	0.00115	CcSEcCtD
Ondansetron—Angiopathy—Methotrexate—testicular cancer	0.000344	0.00114	CcSEcCtD
Ondansetron—Immune system disorder—Methotrexate—testicular cancer	0.000343	0.00114	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—testicular cancer	0.000342	0.00114	CcSEcCtD
Ondansetron—Mediastinal disorder—Methotrexate—testicular cancer	0.000342	0.00114	CcSEcCtD
Ondansetron—Chills—Methotrexate—testicular cancer	0.000341	0.00113	CcSEcCtD
Ondansetron—Diarrhoea—Cisplatin—testicular cancer	0.000336	0.00112	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—testicular cancer	0.000336	0.00111	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—testicular cancer	0.000335	0.00111	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—testicular cancer	0.000332	0.0011	CcSEcCtD
Ondansetron—Hypersensitivity—Etoposide—testicular cancer	0.000332	0.0011	CcSEcCtD
Ondansetron—Erythema—Methotrexate—testicular cancer	0.00033	0.0011	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—testicular cancer	0.00033	0.0011	CcSEcCtD
Ondansetron—Flushing—Epirubicin—testicular cancer	0.00033	0.00109	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—testicular cancer	0.00033	0.00109	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—testicular cancer	0.000329	0.00109	CcSEcCtD
Ondansetron—Asthenia—Etoposide—testicular cancer	0.000323	0.00107	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—testicular cancer	0.000322	0.00107	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—testicular cancer	0.000321	0.00106	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—testicular cancer	0.00032	0.00106	CcSEcCtD
Ondansetron—Chills—Epirubicin—testicular cancer	0.000319	0.00106	CcSEcCtD
Ondansetron—Pruritus—Etoposide—testicular cancer	0.000318	0.00106	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—testicular cancer	0.000317	0.00105	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—testicular cancer	0.000317	0.00105	CcSEcCtD
Ondansetron—Vomiting—Cisplatin—testicular cancer	0.000312	0.00104	CcSEcCtD
Ondansetron—Vision blurred—Methotrexate—testicular cancer	0.000311	0.00103	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—testicular cancer	0.000311	0.00103	CcSEcCtD
Ondansetron—Rash—Cisplatin—testicular cancer	0.00031	0.00103	CcSEcCtD
Ondansetron—Dermatitis—Cisplatin—testicular cancer	0.00031	0.00103	CcSEcCtD
Ondansetron—Erythema—Epirubicin—testicular cancer	0.000309	0.00103	CcSEcCtD
Ondansetron—Diarrhoea—Etoposide—testicular cancer	0.000308	0.00102	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—testicular cancer	0.000307	0.00102	CcSEcCtD
Ondansetron—Ill-defined disorder—Methotrexate—testicular cancer	0.000307	0.00102	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—testicular cancer	0.000305	0.00101	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—testicular cancer	0.000305	0.00101	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—testicular cancer	0.000305	0.00101	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—testicular cancer	0.000298	0.00099	CcSEcCtD
Ondansetron—Malaise—Methotrexate—testicular cancer	0.000298	0.000989	CcSEcCtD
Ondansetron—Dizziness—Etoposide—testicular cancer	0.000298	0.000988	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—testicular cancer	0.000297	0.000985	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—testicular cancer	0.000296	0.000983	CcSEcCtD
Ondansetron—Chills—Doxorubicin—testicular cancer	0.000295	0.000979	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—testicular cancer	0.000294	0.000974	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—testicular cancer	0.000291	0.000967	CcSEcCtD
Ondansetron—Cough—Methotrexate—testicular cancer	0.000288	0.000957	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—testicular cancer	0.000287	0.000952	CcSEcCtD
Ondansetron—Convulsion—Methotrexate—testicular cancer	0.000286	0.00095	CcSEcCtD
Ondansetron—Vomiting—Etoposide—testicular cancer	0.000286	0.00095	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—testicular cancer	0.000286	0.000949	CcSEcCtD
Ondansetron—Agitation—Epirubicin—testicular cancer	0.000284	0.000943	CcSEcCtD
Ondansetron—Rash—Etoposide—testicular cancer	0.000284	0.000942	CcSEcCtD
Ondansetron—Dermatitis—Etoposide—testicular cancer	0.000284	0.000941	CcSEcCtD
Ondansetron—Headache—Etoposide—testicular cancer	0.000282	0.000936	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—testicular cancer	0.000282	0.000936	CcSEcCtD
Ondansetron—Chest pain—Methotrexate—testicular cancer	0.000281	0.000933	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000279	0.000927	CcSEcCtD
Ondansetron—Malaise—Epirubicin—testicular cancer	0.000279	0.000925	CcSEcCtD
Ondansetron—Discomfort—Methotrexate—testicular cancer	0.000278	0.000922	CcSEcCtD
Ondansetron—Syncope—Epirubicin—testicular cancer	0.000277	0.00092	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—testicular cancer	0.000273	0.000907	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—testicular cancer	0.000272	0.000902	CcSEcCtD
Ondansetron—Cough—Epirubicin—testicular cancer	0.00027	0.000895	CcSEcCtD
Ondansetron—Anaphylactic shock—Methotrexate—testicular cancer	0.00027	0.000895	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—testicular cancer	0.00027	0.000895	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—testicular cancer	0.000268	0.000889	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—testicular cancer	0.000265	0.000881	CcSEcCtD
Ondansetron—Nervous system disorder—Methotrexate—testicular cancer	0.000264	0.000878	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—testicular cancer	0.000263	0.000874	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—testicular cancer	0.000263	0.000872	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—testicular cancer	0.000262	0.000871	CcSEcCtD
Ondansetron—Skin disorder—Methotrexate—testicular cancer	0.000262	0.000869	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000261	0.000868	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—testicular cancer	0.00026	0.000863	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—testicular cancer	0.000258	0.000856	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—testicular cancer	0.000257	0.000854	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—testicular cancer	0.000257	0.000851	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—testicular cancer	0.000253	0.000839	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—testicular cancer	0.000252	0.000837	CcSEcCtD
Ondansetron—Hypotension—Methotrexate—testicular cancer	0.000252	0.000836	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—testicular cancer	0.000251	0.000834	CcSEcCtD
Ondansetron—Cough—Doxorubicin—testicular cancer	0.00025	0.000828	CcSEcCtD
Ondansetron—Shock—Epirubicin—testicular cancer	0.000248	0.000824	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—testicular cancer	0.000248	0.000823	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—testicular cancer	0.000247	0.000821	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—testicular cancer	0.000246	0.000817	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—testicular cancer	0.000245	0.000813	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—testicular cancer	0.000244	0.000808	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—testicular cancer	0.000243	0.000806	CcSEcCtD
Ondansetron—Paraesthesia—Methotrexate—testicular cancer	0.000242	0.000804	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000242	0.000803	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—testicular cancer	0.000241	0.000799	CcSEcCtD
Ondansetron—Dyspnoea—Methotrexate—testicular cancer	0.00024	0.000798	CcSEcCtD
Ondansetron—SLC47A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00024	0.0517	CbGpPWpGaD
Ondansetron—Somnolence—Methotrexate—testicular cancer	0.00024	0.000796	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—testicular cancer	0.000238	0.000791	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—testicular cancer	0.000236	0.000783	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—testicular cancer	0.000233	0.000775	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000233	0.000773	CcSEcCtD
Ondansetron—Fatigue—Methotrexate—testicular cancer	0.000232	0.000772	CcSEcCtD
Ondansetron—Pain—Methotrexate—testicular cancer	0.000231	0.000765	CcSEcCtD
Ondansetron—Shock—Doxorubicin—testicular cancer	0.00023	0.000762	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—testicular cancer	0.000229	0.00076	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—testicular cancer	0.000228	0.000756	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—testicular cancer	0.000227	0.000753	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—testicular cancer	0.000227	0.000752	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—testicular cancer	0.000225	0.000747	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—testicular cancer	0.000224	0.000744	CcSEcCtD
Ondansetron—Feeling abnormal—Methotrexate—testicular cancer	0.000222	0.000737	CcSEcCtD
Ondansetron—Gastrointestinal pain—Methotrexate—testicular cancer	0.00022	0.000732	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—testicular cancer	0.000218	0.000724	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000218	0.000723	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—testicular cancer	0.000218	0.000722	CcSEcCtD
Ondansetron—Pain—Epirubicin—testicular cancer	0.000216	0.000716	CcSEcCtD
Ondansetron—Constipation—Epirubicin—testicular cancer	0.000216	0.000716	CcSEcCtD
Ondansetron—Urticaria—Methotrexate—testicular cancer	0.000214	0.000711	CcSEcCtD
Ondansetron—Abdominal pain—Methotrexate—testicular cancer	0.000213	0.000707	CcSEcCtD
Ondansetron—Body temperature increased—Methotrexate—testicular cancer	0.000213	0.000707	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—testicular cancer	0.00021	0.000696	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—testicular cancer	0.000208	0.000691	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—testicular cancer	0.000208	0.00069	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—testicular cancer	0.000208	0.000689	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—testicular cancer	0.000206	0.000685	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000202	0.000669	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—testicular cancer	0.000201	0.000668	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—testicular cancer	0.0002	0.000665	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—testicular cancer	0.0002	0.000663	CcSEcCtD
Ondansetron—Pain—Doxorubicin—testicular cancer	0.0002	0.000663	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—testicular cancer	0.000199	0.000662	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—testicular cancer	0.000199	0.000662	CcSEcCtD
Ondansetron—Hypersensitivity—Methotrexate—testicular cancer	0.000199	0.000659	CcSEcCtD
Ondansetron—Asthenia—Methotrexate—testicular cancer	0.000193	0.000642	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—testicular cancer	0.000192	0.000639	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000191	0.000634	CcSEcCtD
Ondansetron—Pruritus—Methotrexate—testicular cancer	0.000191	0.000633	CcSEcCtD
Ondansetron—SLC47A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000189	0.0408	CbGpPWpGaD
Ondansetron—Hypersensitivity—Epirubicin—testicular cancer	0.000186	0.000617	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—testicular cancer	0.000185	0.000616	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—testicular cancer	0.000185	0.000613	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—testicular cancer	0.000185	0.000613	CcSEcCtD
Ondansetron—Diarrhoea—Methotrexate—testicular cancer	0.000184	0.000612	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—testicular cancer	0.000181	0.000601	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—testicular cancer	0.000179	0.000592	CcSEcCtD
Ondansetron—Dizziness—Methotrexate—testicular cancer	0.000178	0.000592	CcSEcCtD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000178	0.0383	CbGpPWpGaD
Ondansetron—Diarrhoea—Epirubicin—testicular cancer	0.000173	0.000573	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—testicular cancer	0.000172	0.000571	CcSEcCtD
Ondansetron—Vomiting—Methotrexate—testicular cancer	0.000171	0.000569	CcSEcCtD
Ondansetron—Rash—Methotrexate—testicular cancer	0.00017	0.000564	CcSEcCtD
Ondansetron—Dermatitis—Methotrexate—testicular cancer	0.00017	0.000564	CcSEcCtD
Ondansetron—Headache—Methotrexate—testicular cancer	0.000169	0.000561	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—testicular cancer	0.000168	0.000556	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—testicular cancer	0.000167	0.000554	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—testicular cancer	0.000165	0.000548	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—testicular cancer	0.00016	0.000532	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—testicular cancer	0.00016	0.00053	CcSEcCtD
Ondansetron—Rash—Epirubicin—testicular cancer	0.000159	0.000528	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—testicular cancer	0.000159	0.000528	CcSEcCtD
Ondansetron—Headache—Epirubicin—testicular cancer	0.000158	0.000525	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—testicular cancer	0.000154	0.000512	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—testicular cancer	0.000148	0.000493	CcSEcCtD
Ondansetron—Rash—Doxorubicin—testicular cancer	0.000147	0.000489	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—testicular cancer	0.000147	0.000488	CcSEcCtD
Ondansetron—Headache—Doxorubicin—testicular cancer	0.000146	0.000485	CcSEcCtD
Ondansetron—KCNH2—Hematopoietic Stem Cell Differentiation—KITLG—testicular cancer	0.000138	0.0296	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—INSL3—testicular cancer	0.000135	0.0291	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000122	0.0263	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—INSL3—testicular cancer	9.77e-05	0.021	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.25e-05	0.0199	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—BCL10—testicular cancer	8.67e-05	0.0187	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—INSL3—testicular cancer	7.65e-05	0.0165	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	7.42e-05	0.016	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—INSL3—testicular cancer	6.94e-05	0.015	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.55e-05	0.0141	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	5.66e-05	0.0122	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—INSL3—testicular cancer	5.65e-05	0.0122	CbGpPWpGaD
Ondansetron—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	5.46e-05	0.0117	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—INSL3—testicular cancer	4.99e-05	0.0107	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	4.98e-05	0.0107	CbGpPWpGaD
Ondansetron—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	4.66e-05	0.01	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—INSL3—testicular cancer	4.31e-05	0.00927	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—INSL3—testicular cancer	4.1e-05	0.00883	CbGpPWpGaD
Ondansetron—CYP3A7—Biological oxidations—HPGDS—testicular cancer	3.98e-05	0.00858	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—INSL3—testicular cancer	3.19e-05	0.00688	CbGpPWpGaD
Ondansetron—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	2.97e-05	0.00639	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—INSL3—testicular cancer	2.9e-05	0.00625	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—HPGDS—testicular cancer	2.89e-05	0.00621	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—HPGDS—testicular cancer	2.88e-05	0.0062	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—INSL3—testicular cancer	2.82e-05	0.00607	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—INSL3—testicular cancer	2.56e-05	0.00551	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—INSL3—testicular cancer	2.43e-05	0.00524	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—INSL3—testicular cancer	2.21e-05	0.00476	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—HPGDS—testicular cancer	2.05e-05	0.00441	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—HPGDS—testicular cancer	2.03e-05	0.00437	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—HPGDS—testicular cancer	1.74e-05	0.00374	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—INSL3—testicular cancer	1.71e-05	0.00369	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—INSL3—testicular cancer	1.51e-05	0.00326	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.34e-05	0.00288	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—H2AFZ—testicular cancer	1.31e-05	0.00283	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—INSL3—testicular cancer	1.31e-05	0.00281	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—STK11—testicular cancer	1.31e-05	0.00281	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—KITLG—testicular cancer	1.21e-05	0.0026	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—FGFR3—testicular cancer	8.98e-06	0.00193	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—KIT—testicular cancer	8.24e-06	0.00177	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.8e-06	0.00168	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—HPGDS—testicular cancer	6.81e-06	0.00147	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.66e-06	0.00143	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—H2AFZ—testicular cancer	5.49e-06	0.00118	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STK11—testicular cancer	5.45e-06	0.00117	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KITLG—testicular cancer	5.05e-06	0.00109	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—STK11—testicular cancer	4.95e-06	0.00107	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—HPGDS—testicular cancer	4.94e-06	0.00106	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—HPGDS—testicular cancer	4.93e-06	0.00106	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—H2AFZ—testicular cancer	4.84e-06	0.00104	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STK11—testicular cancer	4.81e-06	0.00104	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KITLG—testicular cancer	4.45e-06	0.000959	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	4.18e-06	0.0009	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STK11—testicular cancer	4.16e-06	0.000895	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KITLG—testicular cancer	3.84e-06	0.000828	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—FGFR3—testicular cancer	3.75e-06	0.000808	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—STK11—testicular cancer	3.59e-06	0.000772	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—STK11—testicular cancer	3.58e-06	0.000771	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HPGDS—testicular cancer	3.5e-06	0.000754	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HPGDS—testicular cancer	3.47e-06	0.000748	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KIT—testicular cancer	3.44e-06	0.000742	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—FGFR3—testicular cancer	3.31e-06	0.000713	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KIT—testicular cancer	3.04e-06	0.000654	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HPGDS—testicular cancer	2.97e-06	0.000639	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—FGFR3—testicular cancer	2.86e-06	0.000615	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KIT—testicular cancer	2.62e-06	0.000565	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—STK11—testicular cancer	2.55e-06	0.000548	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—STK11—testicular cancer	2.52e-06	0.000543	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HPGDS—testicular cancer	2.29e-06	0.000493	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—STK11—testicular cancer	2.16e-06	0.000464	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—STK11—testicular cancer	1.66e-06	0.000358	CbGpPWpGaD
